

# PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
Name	Execution Date
TPG-AXON ROYALTY TRUST	12/30/2009
<b>RECEIVING PARTY DATA</b>	
Name:	TPG-AXON LEX SUB-TRUST
Street Address:	c/o U.S. BANK TRUST NATIONAL ASSOCIATION, 300 DELAWARE AVE, 9TH FL
City:	WILMINGTON
State/Country:	DELAWARE
Postal Code:	19801
<b>PROPERTY NUMBERS Total: 27</b>	
Property Type	Number
PCT Number:	US0040281
PCT Number:	US0017095
PCT Number:	US0105831
PCT Number:	US0323511
PCT Number:	US0402304
PCT Number:	US0537368
PCT Number:	US0703022
Patent Number:	6403567
Patent Number:	6642210
Patent Number:	7183264
Patent Number:	7144872
Application Number:	11588834
Patent Number:	6214807
Patent Number:	6855818
Patent Number:	6770634

CH \$1080.00 US0040281

**501058136**

**PATENT**  
**REEL: 023731 FRAME: 0916**

Patent Number:	7109180
Application Number:	11522120
Application Number:	11070768
Application Number:	10629368
Application Number:	10766403
Application Number:	11253322
Application Number:	11701699
Application Number:	11750295
Application Number:	11766964
Application Number:	11848743
Application Number:	11864437
Application Number:	11969047

# CORRESPONDENCE DATA

Fax Number: (415)693-2222

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 4156932440

Email: crhem@cooley.com

Correspondent Name: Cooley Godward Kronish LLP

Address Line 1: 101 California Street, 5th Floor

Address Line 4: San Francisco, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	TPG-AXON 305501-129
-------------------------	---------------------

NAME OF SUBMITTER:	C. Rhem
--------------------	---------

Total Attachments: 6  
source=TPG#page1.tif  
source=TPG#page2.tif  
source=TPG#page3.tif  
source=TPG#page4.tif  
source=TPG#page5.tif  
source=TPG#page6.tif

## PATENT ASSIGNMENT

This Patent Assignment dated as of December 30, 2009 (the "*Assignment*"), is entered into by and between **TPG-AXON ROYALTY TRUST**, a trust established under the laws of the Republic of Ireland, and its permitted successors and assigns ("*Assignor*"), and **TPG-AXON LEX SUB-TRUST**, a Delaware statutory trust, and its permitted successors and assigns ("*Assignee*").

### RECITALS:

**A.** Assignor is a party to (i) that certain Asset Sale and Purchase Agreement dated as of April 10, 2008 (the "*Purchase Agreement*"), by and between Assignor and Gilead Palo Alto, Inc. (formerly known as CV Therapeutics, Inc.), a Delaware corporation (the "*Company*") and (ii) that certain Intellectual Property Security Agreement dated as of April 15, 2008 (the "*Intellectual Property Security Agreement*"), by and between Assignor and the Company pursuant to which the Company granted to Assignor a continuing security interest in the patents listed on Exhibit A attached hereto (the "*Patents*");

**B.** Patent assignments with respect to the above described security interest were duly recorded on April 16, 2008 (Reel/Frame 020808/0823) and October 6, 2009 (Reel/Frame 023330/0648) with the United States Patent and Trademark Office ;

**C.** Assignor and Assignee entered into a Contribution and Exchange Agreement dated as of December 30, 2009 (the "*Contribution Agreement*") pursuant to which Assignor assigned its security interest in the Patents to Assignee; and

**D.** Assignor and Assignee desire to record the assignment of the above described security interest in the Patents by entering into and recording this Assignment with the United States Patent and Trademark Office.

### AGREEMENT:

**NOW, THEREFORE**, in consideration of the promises and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

**1.** Effective on and as of Closing Date (as defined in the Contribution Agreement), Assignor transfers and assigns to Assignee all of its right, title and interest in, to, and under the Purchase Agreement and the Intellectual Property Security Agreement, including without limitation, Assignor's security interest in the Patents, and Assignee does accept this assignment and expressly assumes and agrees to thereafter perform all of the terms, covenants, conditions and obligations of Assignor under the Purchase Agreement and the Intellectual Property Security Agreement.

**2.** This Assignment shall be binding on and inure to the benefit of the parties hereto, their administrators, successors in interest and assigns.

3. This Assignment may be executed in any number of counterparts, and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Assignment. Delivery of an executed counterpart of this Assignment by telefacsimile or electronic delivery shall be equally as effective as delivery of an original executed counterpart of this Assignment.


4. This Assignment shall be governed by and construed, interpreted and enforced in accordance with the laws of the State of New York, as applied to agreements executed and performed entirely in New York, without giving effect to the principles of conflicts of law thereof other than Section 5-1401 of the General Obligations Law of the State of New York.

IN WITNESS WHEREOF, Assignor and Assignee have executed this Assignment the day and year first above written.

**ASSIGNOR:**

**TPG-Axon Royalty Trust**


By: TPG-Axon Capital (Ireland), Limited,  
its manager

By:   
Name: Dinakar Singh  
Title: Director

**ASSIGNEE:**

**TPG-Axon Lex Sub-Trust**

By: TPG-Axon Capital Management, L.P.,  
its Administrator

By:   
Name: Mary Lee  
Title: Chief Legal Officer

**EXHIBIT A****PATENTS**

<i>Country</i>	<i>Application No.</i>	<i>Patent / Publication No.</i>	<i>Title</i>
Patent Cooperation Treaty ("PCT")	PCT/US00/40281	WO 00/78779 A2	N-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
PCT	PCT/US00/17095	WO 00/78778 A2	C-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
PCT	PCT/US01/05831	WO 01/62979 A2	METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A <sub>2A</sub> RECEPTOR
PCT	PCT/US03/23511	WO 2004/011010 A1	MYOCARDIAL PERFUSION IMAGING USING A <sub>2A</sub> RECEPTOR AGONISTS
PCT	PCT/US04/002304	WO 2005/082379 A1	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS
PCT	PCT/US2005/037368	WO 2006/044856 A2	USE OF A <sub>2A</sub> ADENOSINE RECEPTOR AGONISTS
PCT	PCT/US2007/003022	WO 2007/092372 A1	PROCESS FOR PREPARING AN A <sub>2A</sub> -ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
United States	US 09/338,185	US 6,403,567 B1	N-PYRAZOLE A <sub>2A</sub> ADENOSINE RECEPTOR AGONISTS
United States	US 10/018,446	US 6,642,210 B1	2-(N-PYRAZOLO)ADENOSINES WITH APPLICATION AS ADENOSINE A <sub>2A</sub> RECEPTOR AGONISTS
United States	US 10/652,378	US 7,183,264 B2	N-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
United States	US 11/252,760	US 7,144,872 B2	N-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
United States	US 11/588,834	US 2007/0203090 A1	N-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
United States	US 09/338,327	US 6,214,807 B1	C-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
United States	US 09/812,176	US 6,855,818 B2	C-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
United States	US 10/018,758	US 6,770,634 B1	C-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
United States	US 10/813,535	US 7,109,180 B2	C-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
United	US 11/522,120	US	C-PYRAZOLE A <sub>2A</sub> RECEPTOR

<b>Country</b>	<b>Application No.</b>	<b>Patent / Publication No.</b>	<b>Title</b>
States		2007/0207978 A1	AGONISTS
United States	US 11/070,768	US 2005/0175535 A1	MYOCARDIAL PERFUSION IMAGING METHOD
United States	US 10/629,368	US 2004/0064039 A1	MYOCARDIAL PERFUSION IMAGING METHOD
United States	US 10/766,403	US 2005/0020915 A1	MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS
United States	US 11/253,322	US 2006/0084625 A1	USE OF A <sub>2A</sub> ADENOSINE RECEPTOR AGONISTS
United States	US 11/701,699	US 2007/0265445 A1	PROCESS FOR PREPARING AN A <sub>2A</sub> -ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
United States	US 11/750,295	US 2007/0225247 A1	PROCESS FOR PREPARING AN A <sub>2A</sub> -ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
United States	US 11/766,964	US 2007/0299089 A1	USE OF A <sub>2A</sub> ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA
United States	US 11/848,743	Not published	METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS
United States	US 11/864,437	Not published	METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE
United States	US 11/969,047	Not published	MYOCARDIAL PERFUSION IMAGING
Canada	CA2000002377746	CA2377746 C	N-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
Canada	CA2000002375430	CA2375430 C	C-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
Canada	CA2001002439222	CA2439222AA	METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A <sub>2A</sub> RECEPTOR
Canada	CA2003002492855	CA2492855AA	MYOCARDIAL PERFUSION IMAGING USING A <sub>2A</sub> RECEPTOR AGONISTS

<i>Country</i>	<i>Application No.</i>	<i>Patent / Publication No.</i>	<i>Title</i>
Canada	CA2004002554169	CA2554169AA	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS
Canada	CA2005002583185	CA2583185AA	USE OF A <sub>2A</sub> ADENOSINE RECEPTOR AGONISTS
Mexico	MX2001PA0013325	MX244944	N-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
Mexico	MX2001PA0013350	MX245023	C-PYRAZOLE A <sub>2A</sub> RECEPTOR AGONISTS
Mexico	MX2005PA0001123	Only abstract published	MYOCARDIAL PERFUSION IMAGING USING A <sub>2A</sub> RECEPTOR AGONISTS
Mexico	MX2006PA008521	Only abstract published	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS
Mexico	MX2007PA004749	Only abstract published	USE OF A <sub>2A</sub> ADENOSINE RECEPTOR AGONISTS